Phase Ib safety, preliminary antileukemic activity and biomarker analysis of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with low-dose cytarabine or decitabine in patients with relapsed or refractory acute myeloid leukemia-MedSci.cn

Phase Ib safety, preliminary antileukemic activity and biomarker analysis of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with low-dose cytarabine or decitabine in patients with relapsed or refractory acute myeloid leukemia

Zeidan, AM; Becker, P; Spira, AI; Patel, PA; Schiller, GJ; Tsai, ML; Lin, TL; Ridinger, M; Erlander, M; Silberman, SL; Cortes, JE

CANCER RESEARCH, 2019; 79 (13):

科室
- - 订阅+
  - 更多科室
工具
服务